ArticleSchizophrenia research2021
Depression: An actionable outcome for those at clinical high-risk.
Article in Schizophrenia research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 15 citations in OpenAlex.
- Clinical predictors of at-risk mental states in general adolescent population: a 2-year follow-up study.European child & adolescent psychiatry · 2026Article
- Candidate Targets for Resilience Training to Reduce Transdiagnostic Risk for Mental Illness.Schizophrenia bulletin · 2026Article
- Disrupted hierarchical functional brain organization in affective and psychotic disorders: insights from functional brain gradients.Translational psychiatry · 2026Article
- Transdiagnostic prevention in youth mental health, Part II: interventions.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026Review
- Digital phenotyping evidence for the reduced positivity offset as a mechanism underlying anhedonia among individuals at clinical high-risk for psychosis.Schizophrenia research · 2025Article
- Sample ascertainment and clinical outcome measures in the Accelerating Medicines Partnership® Schizophrenia Program.Schizophrenia (Heidelberg, Germany) · 2025Article
- Baseline Clinical Characterization of Participants in the Accelerating Medicines Partnership Schizophrenia Program.Schizophrenia bulletin open · 2025Article
- Factors Associated with Transition to Serious Mental Illness.Canadian journal of psychiatry. Revue canadienne de psychiatrie · 2024Article
- Psychological and social difficulties in young non-help-seeking adolescents at risk for psychosis: insights from a large cohort study.Frontiers in psychology · 2024Article
- Clinical high risk for psychosis syndrome is associated with reduced neural responding to unpleasant images.Journal of psychopathology and clinical science · 2023Article
- Ketamine Induces Lasting Antidepressant Effects by Modulating the NMDAR/CaMKII-Mediated Synaptic Plasticity of the Hippocampal Dentate Gyrus in Depressive Stroke Model.Neural plasticity · 2021Article
- Commentary. Toward a core outcomes assessment set for clinical high risk.Schizophrenia research · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 8 institutions in 2 countries.
Funding
Abstract
Comorbid diagnoses are common in youth who are at clinical high-risk (CHR) for developing psychosis, with depression being the most common. The aim of this paper is to examine depression over two years in a large sample of CHR youth who do not make the transition to psychosis, considering both categorical and dimensional ratings of depression severity. The sample consisted of 267 CHR youth who were followed for two years. Based on DSM-IV diagnoses over this time period, 100 CHR individuals never received a diagnosis of depression, 64 individuals continuously met criteria for depression, 92 individuals received a diagnosis of depression at one or more timepoints, and 11 participants had a diagnosis of depression only at 24-months. These groupings were supported by six-monthly ratings on the Calgary Depression Scale. The majority of this sample experienced a major depressive episode on more than one occasion, suggesting that depression and depressive symptoms identify a domain of substantial unmet clinical need. Recommendations are that depression in CHR youth and young adults should be monitored more frequently and that there is a need for clinical trials to address depression systematically in this vulnerable population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.